Asenapine

Drug Profile

Asenapine

Alternative Names: Asenapine maleate; Atisenap; ME2136; ORG-5222; Saphris; SCH-900274; Sycrest

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Organon
  • Developer Allergan; Lundbeck A/S; Meiji Seika Pharma; Merck & Co
  • Class Antipsychotics; Heterocyclic compounds with 4 or more rings; Oxepins; Pyrrolidines; Small molecules
  • Mechanism of Action Alpha adrenergic receptor antagonists; Dopamine receptor antagonists; Histamine H1 receptor antagonists; Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Schizophrenia

Most Recent Events

  • 20 Jul 2017 Merck terminates a phase II trial as the funding ended due to recruitment delays for Bipolar disorders in USA (PO) (NCT01807741)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia(In children) in USA (Sublingual, Tablet)
  • 17 Jul 2015 Launched for Bipolar disorders (In adolescents, In children) in USA (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top